ABOUT BACH PHARMA
Bach Pharma, Inc. is dedicated to the discovery, development and commercialization of new therapeutics for the treatment of life threatening oxidative stress-related Diseases And Other Serious Illnesses.
Bach’s lead candidate GVT® is a novel cytoprotective agent. GVT® has powerful anti-oxidant and anti-inflammatory properties and scavenges free radicals. Research has shown that GVT® is a redox buffering molecule, a heavy metal chelator, as well as a regulator of proteostasis and Nrf2. GVT® has the ability to cross the blood-brain barrier and enter cells of the central nervous system, as well as to enter the immune system, thereby delivering therapeutic results to the gut, thymus, spleen and blood. It is also able to cross the retinal-brain barrier.Bach, in collaboration with The University of Texas’s M.D Anderson Cancer Center and Harvard Medical School have assisted and supported ongoing studies and trials with the Company’s products. Additional studies have been or are currently underway at Northwestern University, Texas A&M University, University of Massachusetts Medical School, Baylor University, Colorado State University, University of North Carolina, Duke University, University of South Florida, as well as other universities around the world. The products have been under advanced study by the Department of Defense and The Veterans Administration.
NEWS & EVENTS
Annual Shareholder Meeting: March 19, 2016 200 Westpark Corporate Center 4364 South Alston Avenue Durham, NC 27713-2280
Board of Directors Meeting: March 20, 2016 Durham, NC 200 Westpark Corporate Center 4364 South Alston Avenue Durham, NC 27713-2280
January 30, 2016
February 10, 2013
February 1, 2013
June 30, 2011
April 20, 2011
January 4, 2010